Compare IDEXX Laboratories, Inc. (IDXX) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Kyndryl Holdings Inc — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Kyndryl Holdings Inc trades at $12.15 (market cap $2.69B). The key difference: IDEXX Laboratories, Inc. is far larger — about 16.5× Kyndryl Holdings Inc's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| IDXX | KD | |
|---|---|---|
Market Cap | $44.48B | $2.69B |
Sector | Health | Technology |
52-Week High | $766.68 | $39.47 |
52-Week Low | $520.87 | $10.59 |
Enterprise Value | $45.38B | $5.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Kyndryl Holdings (KD) trades at $12.195, up 0.37% on the day, with a neutral technical signal and bullish moving averages. The company reported revenue of $15.06B in 2025, turning profitable with net income of $252M after years of losses. Recent news includes leadership changes, partnership expansions with Microsoft and AWS, and multiple law firm investigations into corporate governance, creating mixed sentiment.
The outlook is cautiously optimistic with a consensus price target of $14.00, implying 15% upside, but risks include ongoing legal probes, volatile earnings history with recent misses, and high debt levels. Improved cash flow and strategic alliances support growth, yet investor confidence remains tempered by governance concerns and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
